Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD (MLTX)

141 + Investors. Track Smart Money conviction in MLTX. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -13
Streak
1Q ▼
Buyers last Q
55%

Smart Money Signals — MLTX

Based on 127 hedge funds · latest filing: 2025 Q4 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their MLTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 91% of 3.0Y peak

91% of all-time peak
127 funds currently hold this stock — 91% of the 3.0-year high of 140 funds (reached 2025 Q3). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +13% more funds vs a year ago

fund count last 6Q
+15 new funds entered over the past year (+13% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 55% buying

102 buying83 selling
Last quarter: 102 funds bought or added vs 83 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 37 → 22 → 49 → 42. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
📌

Mixed — 39% long-term, 43% new

39% conviction (2yr+) 19% medium 43% new
Of the 127 current holders: 49 (39%) held >2 years, 24 held 1–2 years, and 54 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.
💰

Value +157% but shares only +39% — price-driven

Value
+156%
Shares
+39%
Last quarter: the total dollar value of institutional holdings rose +157%, but actual share count only changed +39%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

20 → 37 → 22 → 49 → 42 new funds/Q
New funds entering each quarter: 37 → 22 → 49 → 42. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Deep conviction — 49% of holders stayed 2+ years

49% veterans 15% 1-2yr 36% new
Of 141 current holders: 69 (49%) have held for over 2 years without selling. These are not momentum buyers — they have lived through drawdowns and stayed. A large veteran base acts as a stabilizing force during selloffs.
📋

Smaller funds dominant — 9% AUM from top-100

9% from top-100 AUM funds
23 of 127 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Hedge Fund Ownership: MLTX

How many hedge funds hold MLTX — quarterly history vs. share price
Quarterly hedge fund ownership of MLTX vs. share price

Market Analysis: MLTX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MLTX

-- --
Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

17 top-rated funds 2 high-conviction
Consensus
5.5
/ 10
breadth
×
Elite
1.8
/ 10
conviction
Hedge Fund Positioning: MLTX
2026 Q1 Stats Unlock in 22 days 141 + Investors

Track Smart Money conviction in MLTX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2025 Q4) Prior (2025 Q3) Change
Funds Holding 141 165 -14.55%
13F Shares 60M 43M 39.19%
Total Value $777M $303M 156.69%
New Positions 43 55 -12
Increased Positions 84 67 +17
Closed Positions 67 38 +29
Reduced Positions 37 57 -20
Total Calls 9 27 -66.67%
Total Puts 7 10 -30.0%
PUT/CALL Ratio 0.78 0.37 Neutral

Statistics: MLTX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

141 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MLTX. Verified SEC 13F-HR filings.

Top 6 institutional holders of MLTX — 2025 Q4 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Y-Intercept (Hong Kong) Ltd 0.04% 127,087 $2.4M
2 CONGRESS ASSET MANAGEMENT CO 0.02% 178,555 $3.3M
3 SIGNATUREFD, LLC 0.00% 2,267 $42K
4 SG Americas Securities, LLC 0.00% 9,350
5 Farther Finance Advisors, LLC 0.00% 733 $12K
6 SBI Securities Co., Ltd. 0.00% 213 $4K
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD (MLTX)

What does the Smart Money Trend signal show for MLTX?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their MLTX positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for MLTX?

Slight buying edge — 55% buying: Last quarter: 102 funds bought or added vs 83 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MLTX holders?

Smaller funds dominant — 9% AUM from top-100: 23 of 127 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held MLTX?

Mixed — 39% long-term, 43% new: Of the 127 current holders: 49 (39%) held >2 years, 24 held 1–2 years, and 54 entered in the last year. A mixed base — the stock has long-term believers but also recent buyers who haven't been tested by a downturn yet.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.